{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T04:15:43Z","timestamp":1747282543274,"version":"3.40.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,14]]},"DOI":"10.7759\/cureus.84126","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T22:53:33Z","timestamp":1747263213000},"source":"Crossref","is-referenced-by-count":0,"title":["Atypical Femoral Fracture in Patients With Metastatic Bone Tumors: An Analysis Based on the Japanese Adverse Drug Event Reaction Database (JADER)"],"prefix":"10.7759","author":[{"given":"Yuka","family":"Aimono","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomiko","family":"Sunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Yonezawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Tsuboya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"Kogo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinjiro","family":"Tsuge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ako","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen LS","year":"2003","unstructured":"Rosen LS, Gordon D, Kaminski M, et al.. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003, 98:1735-44. 10.1002\/cncr.11701","journal-title":"Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck AT","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, et al.. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010, 28:5132-9. 10.1200\/JCO.2010.29.7101","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy","volume":"90","author":"Odvina CV","year":"2005","unstructured":"Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005, 90:1294-301. 10.1210\/jc.2004-0952","journal-title":"J Clin Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research","volume":"25","author":"Shane E","year":"2010","unstructured":"Shane E, Burr D, Ebeling PR, et al.. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010, 25:2267-94. 10.1002\/jbmr.253","journal-title":"J Bone Miner Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/17453674.2016.1277412","article-title":"Atypical femoral fractures mimicking metastatic lesions in 2 patients taking denosumab","volume":"88","author":"Austin DC","year":"2017","unstructured":"Austin DC, Torchia MT, Klare CM, Cantu RV. Atypical femoral fractures mimicking metastatic lesions in 2 patients taking denosumab. Acta Orthop. 2017, 88:351-3. 10.1080\/17453674.2016.1277412","journal-title":"Acta Orthop"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000002058","article-title":"Impending atypical femoral fracture in a patient of breast cancer with bone metastases receiving long-term denosumab","volume":"43","author":"Sugihara T","year":"2018","unstructured":"Sugihara T, Koizumi M, Hayakawa K, Ito Y, Sata N. Impending atypical femoral fracture in a patient of breast cancer with bone metastases receiving long-term denosumab. Clin Nucl Med. 2018, 43:365-6. 10.1097\/RLU.0000000000002058","journal-title":"Clin Nucl Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a Task Force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler RA","year":"2016","unstructured":"Adler RA, El-Hajj Fuleihan G, Bauer DC, et al.. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016, 31:16-35. 10.1002\/jbmr.2708","journal-title":"J Bone Miner Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1302\/0301-620X.99B3.BJJ-2016-0276.R2","article-title":"Atypical femoral fractures related to bisphosphonate treatment: issues and controversies related to their surgical management","volume":"99-B","author":"Koh A","year":"2017","unstructured":"Koh A, Guerado E, Giannoudis PV. Atypical femoral fractures related to bisphosphonate treatment: issues and controversies related to their surgical management. Bone Joint J. 2017, 99-B:295-302. 10.1302\/0301-620X.99B3.BJJ-2016-0276.R2","journal-title":"Bone Joint J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2012.1796","article-title":"Increasing occurrence of atypical femoral fractures associated with bisphosphonate use","volume":"172","author":"Meier RP","year":"2012","unstructured":"Meier RP, Perneger TV, Stern R, Rizzoli R, Peter RE. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med. 2012, 172:930-6. 10.1001\/archinternmed.2012.1796","journal-title":"Arch Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans SJ","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001, 10:483-6. 10.1002\/pds.677","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref11","article-title":"Osteoporosis Committee of the Japanese Orthopaedic Association Results of the Survey of Registered Cases of Atypical Femur Fractures (AFFs) in 2021 Report of the Project Research Project of the Japanese Orthopaedic Association","author":"Osteoporosis Committee of the Japanese Orthopaedic Association","year":"2023","unstructured":"Osteoporosis Committee of the Japanese Orthopaedic Association. Osteoporosis Committee of the Japanese Orthopaedic Association Results of the Survey of Registered Cases of Atypical Femur Fractures (AFFs) in 2021 Report of the Project Research Project of the Japanese Orthopaedic Association. Japanese Orthopaedic Association, Tokyo, Japan; 2023."},{"key":"ref12","unstructured":"Daiichi Sankyo Company, Limited. RANMARK\u00ae subcutaneous injection 120 mg specific use results survey on long-term use. (2020). Accessed: May 2, 2025: http:\/\/www.medicalcommunity.jp\/sites\/default\/files\/di\/manufacturing_sales_survey\/RMK9PX06.pdf."},{"key":"ref13","unstructured":"FDA Adverse Event Reporting System (FAERS) Public Dashboard. (2024). Accessed. May 2, 2025: https:\/\/fis.fda.gov\/sense\/app\/95239e26-e0be-42d9-a960-9a5f7f1c25ee\/sheet\/6b5a135f-f451-45be-893d-20aaee34e28e\/state\/a...."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-10-165","article-title":"Design and baseline characteristics of a prospective cohort study for determinants of osteoporotic fracture in community-dwelling elderly Japanese men: the Fujiwara-kyo osteoporosis risk in men (FORMEN) study","volume":"10","author":"Iki M","year":"2009","unstructured":"Iki M, Fujita Y, Tamaki J, et al.. Design and baseline characteristics of a prospective cohort study for determinants of osteoporotic fracture in community-dwelling elderly Japanese men: the Fujiwara-kyo osteoporosis risk in men (FORMEN) study. BMC Musculoskelet Disord. 2009, 10:165. 10.1186\/1471-2474-10-165","journal-title":"BMC Musculoskelet Disord"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/ans.12018","article-title":"Burden of bisphosphonate-associated femoral fractures","volume":"83","author":"Shkolnikova J","year":"2013","unstructured":"Shkolnikova J, Flynn J, Choong P. Burden of bisphosphonate-associated femoral fractures. ANZ J Surg. 2013, 83:175-81. 10.1111\/ans.12018","journal-title":"ANZ J Surg"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane E","year":"2014","unstructured":"Shane E, Burr D, Abrahamsen B, et al.. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014, 29:1-23. 10.1002\/jbmr.1998","journal-title":"J Bone Miner Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3109\/17453674.2015.1004149","article-title":"Risk of atypical femoral fracture during and after bisphosphonate use","volume":"86","author":"Schilcher J","year":"2015","unstructured":"Schilcher J, Koeppen V, Aspenberg P, Micha\u00eblsson K. Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop. 2015, 86:100-7. 10.3109\/17453674.2015.1004149","journal-title":"Acta Orthop"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1719","article-title":"Incidence of atypical nontraumatic diaphyseal fractures of the femur","volume":"27","author":"Dell RM","year":"2012","unstructured":"Dell RM, Adams AL, Greene DF, et al.. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res. 2012, 27:2544-50. 10.1002\/jbmr.1719","journal-title":"J Bone Miner Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2012.05.010","article-title":"Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy","volume":"51","author":"Chang ST","year":"2012","unstructured":"Chang ST, Tenforde AS, Grimsrud CD, et al.. Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy. Bone. 2012, 51:524-7. 10.1016\/j.bone.2012.05.010","journal-title":"Bone"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6236-6","article-title":"Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review","volume":"19","author":"Takahashi M","year":"2019","unstructured":"Takahashi M, Ozaki Y, Kizawa R, et al.. Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review. BMC Cancer. 2019, 19:980. 10.1186\/s12885-019-6236-6","journal-title":"BMC Cancer"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.J.01199","article-title":"Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates","volume":"93","author":"Puhaindran ME","year":"2011","unstructured":"Puhaindran ME, Farooki A, Steensma MR, Hameed M, Healey JH, Boland PJ. Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates. J Bone Joint Surg Am. 2011, 93:1235-42. 10.2106\/JBJS.J.01199","journal-title":"J Bone Joint Surg Am"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3705","article-title":"Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab","volume":"11","author":"Lacey DL","year":"2012","unstructured":"Lacey DL, Boyle WJ, Simonet WS, et al.. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012, 11:401-19. 10.1038\/nrd3705","journal-title":"Nat Rev Drug Discov"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70174-8","article-title":"Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial","volume":"14","author":"Amadori D","year":"2013","unstructured":"Amadori D, Aglietta M, Alessi B, et al.. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol. 2013, 14:663-70. 10.1016\/S1470-2045(13)70174-8","journal-title":"Lancet Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial","volume":"317","author":"Himelstein AL","year":"2017","unstructured":"Himelstein AL, Foster JC, Khatcheressian JL, et al.. Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA. 2017, 317:48-58. 10.1001\/jama.2016.19425","journal-title":"JAMA"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2019.100259","article-title":"Atypical femoral fractures from bisphosphonate in cancer patients - review","volume":"18","author":"Lockwood M","year":"2019","unstructured":"Lockwood M, Banderudrappagari R, Suva LJ, Makhoul I. Atypical femoral fractures from bisphosphonate in cancer patients - review. J Bone Oncol. 2019, 18:100259. 10.1016\/j.jbo.2019.100259","journal-title":"J Bone Oncol"},{"key":"ref26","unstructured":"FDA. safety update for osteoporosis drugs, bisphosphonate, and atypical fractures. (2019). Accessed: May 2, 2025: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-safety-update-osteoporosis-drugs...."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2020.100301","article-title":"Incidence of atypical femoral fractures in the treatment of bone metastasis: an alert report","volume":"23","author":"Kaku T","year":"2020","unstructured":"Kaku T, Oh Y, Sato S, et al.. Incidence of atypical femoral fractures in the treatment of bone metastasis: an alert report. J Bone Oncol. 2020, 23:100301. 10.1016\/j.jbo.2020.100301","journal-title":"J Bone Oncol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0192","article-title":"Retrospective review of atypical femoral fracture in metastatic bone disease patients receiving denosumab therapy","volume":"22","author":"Yang SP","year":"2017","unstructured":"Yang SP, Kim TW, Boland PJ, Farooki A. Retrospective review of atypical femoral fracture in metastatic bone disease patients receiving denosumab therapy. Oncologist. 2017, 22:438-44. 10.1634\/theoncologist.2016-0192","journal-title":"Oncologist"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/358931-atypical-femoral-fracture-in-patients-with-metastatic-bone-tumors-an-analysis-based-on-the-japanese-adverse-drug-event-reaction-database-jader","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T22:53:35Z","timestamp":1747263215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/358931-atypical-femoral-fracture-in-patients-with-metastatic-bone-tumors-an-analysis-based-on-the-japanese-adverse-drug-event-reaction-database-jader"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.84126","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,14]]}}}